Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

121. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of harmful effects in non-randomised studies [Cochrane Protocol]

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of harmful effects in non-randomised studies [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2016 PROSPERO

122. Child ADHD and maternal depression: the impact of reporting issues

Child ADHD and maternal depression: the impact of reporting issues Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2016 PROSPERO

123. Systematic review of the effect of structured parental skills training in parents with ADHD

Systematic review of the effect of structured parental skills training in parents with ADHD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

124. Trace element supplements in the treatment of ADHD: a meta-analysis

Trace element supplements in the treatment of ADHD: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2016 PROSPERO

125. Children's ADHD interventions and parenting stress: a meta-analysis

Children's ADHD interventions and parenting stress: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2016 PROSPERO

126. Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final Appraisal Recommendation Advice No: 2615 – September 2015 Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules Submission by Shire Pharmaceuticals Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2534 (...) the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2615: Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules. September 2015. Recommendation of AWMSG Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

2015 All Wales Medicines Strategy Group

127. ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines

ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines (...) ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines Published on: September 15, 2015 Project Number: RC0701-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of switching to another ADHD medication for patients who experience aggression or mood changes secondary to therapy with methylphenidate

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

128. Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines

Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines | CADTH.ca Find the information you need Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Published on: September 3, 2015 Project Number: RB0905-000 Product Line: Research Type: Drug (...) Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence regarding methods of dosage delivery of attention deficit hyperactivity disorder (ADHD) medications to patients with swallowing difficulties? What are the evidence-based guidelines regarding method of dosage delivery of ADHD medications to patients with swallowing difficulties? Key Message One evidence-based guideline was identified regarding methods of dosage delivery of ADHD medications to patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

129. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research

Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD)delivered in school settings: systematic reviews of quantitative and qualitative research Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page

Full Text available with Trip Pro

2015 NIHR HTA programme

130. Medical augmentation of labor and the risk of ADHD in offspring: a population-based study (PubMed)

Medical augmentation of labor and the risk of ADHD in offspring: a population-based study Oxytocin for labor augmentation is widely used in obstetric care in Western countries. Two recent, smaller studies found opposing results regarding the association between prenatal exposure to oxytocin for labor augmentation and attention-deficit/hyperactivity disorder (ADHD). In Denmark, oxytocin is the medication used for nearly all medical augmentations of labor, and we examined the association between (...) medical augmentation of labor and ADHD in a large cohort study based on national register data.All singletons born after spontaneous onset of labor in Denmark between 2000 and 2008 (N = 546 146) were included in the study. Data from the Danish Medical Birth Registry on medical augmentation of labor (yes/no) were used to identify exposed children. ADHD was defined based on the diagnostic codes of International Classification of Diseases, 10th Revision, for hyperkinetic disorder and information

Full Text available with Trip Pro

2015 EvidenceUpdates

131. Parental psychopathology in families of children with ADHD: a meta-analysis

Parental psychopathology in families of children with ADHD: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2015 PROSPERO

132. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane Protocol]

Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

133. Pharmacologic treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults

Pharmacologic treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

134. Psychostimulants for children and adolescents with attention deficit hyperactivity disorder (ADHD). A systematic review and meta-analysis of controlled clinical trials

Psychostimulants for children and adolescents with attention deficit hyperactivity disorder (ADHD). A systematic review and meta-analysis of controlled clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2015 PROSPERO

135. The effectiveness of daily report cards used in school settings for children with, or at risk of, ADHD

The effectiveness of daily report cards used in school settings for children with, or at risk of, ADHD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2015 PROSPERO

136. Effect of stimulants on growth in children and adolescent diagnosed with ADHD

Effect of stimulants on growth in children and adolescent diagnosed with ADHD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2015 PROSPERO

137. Non pharmacological interventions for Attention-Deficit/Hyperactivity Disorder (ADHD) delivered in school settings: a systematic review

Non pharmacological interventions for Attention-Deficit/Hyperactivity Disorder (ADHD) delivered in school settings: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

138. Validating the effect of distinct neurofeedback protocols for children and adolescents with ADHD: the effectiveness on core ADHD symptoms and neurocognitive functions

Validating the effect of distinct neurofeedback protocols for children and adolescents with ADHD: the effectiveness on core ADHD symptoms and neurocognitive functions Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2015 PROSPERO

139. Efficacy of interventions for ADHD: a meta-meta-analysis

Efficacy of interventions for ADHD: a meta-meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2015 PROSPERO

140. Efficacy, safety and treatment discontinuation of pharmacological interventions for adults with ADHD: a meta-analysis and metaregression study

Efficacy, safety and treatment discontinuation of pharmacological interventions for adults with ADHD: a meta-analysis and metaregression study Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO